Khurem Farooq, Verdiva Bio CEO

Aio­los team re­unites with $411M for new biotech with obe­si­ty drugs from Chi­na

There’s a shop­ping bo­nan­za for new obe­si­ty med­i­cines go­ing on among a mar­quee co­hort of bio­phar­ma in­vestors who are in-li­cens­ing treat­ment can­di­dates from Chi­nese and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.